cetylpyridinium chloride anhydrous has been researched along with thalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C | 1 |
| Beppu, H; Fujitani, J; Hinoshita, F; Imai, K; Ohnishi, S; Shioji, S; Tagami, T; Tajima, T | 1 |
2 other study(ies) available for cetylpyridinium chloride anhydrous and thalidomide
| Article | Year |
|---|---|
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue | 2012 |
A nationwide survey regarding the life situations of patients with thalidomide embryopathy in Japan, 2018: First report.
Topics: Family; Family Characteristics; Female; Fetal Diseases; Health; Humans; Income; Japan; Male; Marital Status; Middle Aged; Stress, Psychological; Surveys and Questionnaires; Thalidomide; Work | 2019 |